Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0000908834-25-000097 0001021412 XXXXXXXX LIVE 18 Common Stock, $0.001 par value 09/17/2025 false 0000926617 04537Y208 Aspira Women's Health Inc. 12117 BEE CAVES ROAD BUILDING THREE Suite 100 Austin TX 78738 Jack W. Schuler (520) 906-2991 PO Box 531 Lake Bluff IL 60044 0001021412 N SCHULER JACK W b PF N X1 6536.00 3823829.00 6536.00 3823829.00 3830365.00 N 9.1 IN 0001661351 N Jack W. Schuler Living Trust b WC N IL 0.00 3823829.00 0.00 3823829.00 3823829.00 N 9.1 IN Common Stock, $0.001 par value Aspira Women's Health Inc. 12117 BEE CAVES ROAD BUILDING THREE Suite 100 Austin TX 78738 This Amendment No. 18 to Schedule 13D (this "Amendment") hereby amends and supplements Item 4 by adding the following thereto: "The disclosure set forth in Items 5 and 6 below is hereby incorporated by reference in this Item 4. On September 17, 2025, the Trust purchased from the Issuer the Common Stock and September 2025 Warrants pursuant to the September 2025 Purchase Agreement (in each case as defined and further described in Item 6 below)." This Amendment hereby amends and restates Item 5(a) in its entirety as follows: "The information set forth in Rows 7 through 13 of the cover page hereto for each of Mr. Schuler and the Trust is incorporated herein by reference. The percentage amount set forth in Row 13 for all cover pages filed herewith is calculated based upon the 35,655,918 Shares outstanding as of August 8, 2025, as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 13, 2025 plus the 6,550,000 shares of Common Stock sold pursuant to the September 2025 Purchase Agreement for a total of 42,205,918 Shares outstanding." This Amendment hereby amends and restates Item 5(b) in its entirety as follows: "The information set forth in Rows 7 through 13 of the cover page hereto for each of Mr. Schuler and the Trust is incorporated herein by reference." This Amendment hereby amends and restates Item 5(c) in its entirety as follows: "Neither Mr. Schuler nor the Trust has effected any transactions in the Shares during the 60 days prior to the date hereof." This Amendment hereby amends and restates Item 5(d) in its entirety as follows: "The Trust has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by it and the Shares that it has the right to acquire upon the exercise of 2022 Warrants, January 2024 Warrants, February 2025 Warrants and September 2025 Warrants. Mr. Schuler is the sole trustee of the Trust." This Amendment hereby amends and restates Item 5(d) in its entirety as follows: "Not applicable." This Amendment hereby amends and supplements Item 6 by adding the following thereto: "The disclosure set forth in Items 4 and 5 above is hereby incorporated by reference in this Item 6. September 2025 Purchase Agreement and Common Stock and September 2025 Warrant On September 16, 2025, the Trust entered into a Securities Purchase Agreement, dated as of such date, among the Issuer, the Trust, and the other purchasers party thereto (the "September 2025 Purchase Agreement"), pursuant to which the Trust purchased from the Issuer the Common Stock and September 2025 Warrant (as defined below). The September 2025 Purchase Agreement contained customary terms and conditions. The foregoing description of the September 2025 Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the form thereof attached hereto as Exhibit 16, which exhibit is hereby incorporated herein by reference. On September 16, 2025, pursuant to the September 2025 Purchase Agreement, the Trust purchased from the Issuer 1,111,111 shares of Common Stock (the "Common Stock") and a warrant to purchase 833,333 shares of Common Stock (the "September 2025 Warrant"). The September 2025 Warrant is exercisable at $0.75 per share for five (5) years from the date of issuance. The foregoing description of the September 2025 Warrant does not purport to be complete and is qualified in its entirety by reference to the form thereof attached hereto as Exhibit 17, which exhibit is hereby incorporated herein by reference." This Amendment hereby amends and supplements Item 7 by adding the following thereto: "There is filed herewith as Exhibit 16 the form of September 2025 Purchase Agreement. There is filed herewith as Exhibit 17 the form of September 2025 Warrant." SCHULER JACK W /s/ Jack W Schuler Jack W. Schuler 09/18/2025 Jack W. Schuler Living Trust /s/ Jack W Schuler Jack W Schuler, Sole Trustee 09/18/2025